RxDoctor Payments Data

Rudy Santoso, MD

Psychiatry · Hickory, NCNPI 1023128287

Payments from drug & device makers

$5,780in general payments, 2019–2025

Across 368 payments — averaging $15.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$1K
  • Otsuka America Pharmaceutical, Inc.$786
  • Neurocrine Biosciences, Inc.$625
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$513
  • Alkermes, Inc.$491
  • Teva Pharmaceuticals USA, Inc.$446
  • plus $2K from 14 others

What the payments were for

  • Food & beverage$5,68698%
  • Education$942%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,780 in reported general payments places this provider in the 85th percentile of 1,108 psychiatry providers in North Carolina.

See all psychiatry providers in North Carolina

Medicare billing

Part B allowed, 2024
$11,695
Medicare patients
60
Services billed
176

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine35$209,531
Invega TrinzaPaliperidone Palmitate20$189,887
Invega SustennaPaliperidone Palmitate64$167,591
RexultiBrexpiprazole45$64,978
FanaptIloperidone31$62,411
VraylarCariprazine Hcl39$56,425
TrintellixVortioxetine Hydrobromide67$33,558
Risperdal ConstaRisperidone Microspheres20$21,936
Clozapine91$8,256
Paliperidone ErPaliperidone57$6,159
Quetiapine Fumarate262$4,432
Aripiprazole110$4,427
Ziprasidone Hcl57$3,012
MyrbetriqMirabegron23$2,700
Trazodone Hcl289$2,287

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Trinza, Invega Sustenna, Risperdal Consta$395$379,413104 claims
Teva Pharmaceuticals USA, Inc.Austedo$446$209,53135 claims
Otsuka America Pharmaceutical, Inc.Rexulti$786$64,97845 claims
Vanda Pharmaceuticals Inc.Fanapt$340$62,41131 claims
AbbVieVraylar$227$56,42539 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$66$33,55867 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,108 psychiatry providers in North Carolina.

Other psychiatry in Hickory

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →